Physician profile
Keith A Lerro
NPI 1730161092
$79,562.36
in general payments reported to CMS, 2019-2025
100 companies · $4,640 in 2025
The $4,640 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $4,385 · 2021: $9,727 · 2022: $7,163 · 2023: $10K · 2024: $9,068 · 2025: $4,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $8,568 · Travel and Lodging: $591 · Education: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,358.39 |
| Consulting Fee | $8,567.50 |
| Travel and Lodging | $591.16 |
| Education | $455.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $27,515.40 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $10,357.99 | 2019-2025 | Calquence, Tagrisso, Enhertu |
| Sun Pharmaceutical Industries INC. | $5,144.62 | 2023 | Yonsa |
| Pharmacosmos Therapeutics INC. | $4,416.74 | 2021-2025 | Monoferric, Cosela |
| Global Blood Therapeutics, INC. | $3,277.58 | 2020-2022 | |
| G1 Therapeutics, INC. | $1,606.70 | 2021-2023 | Cosela |
| Merck Sharp & Dohme LLC | $1,601.73 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Dendreon Pharmaceuticals LLC | $1,485.99 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $1,456.30 | 2019-2025 | Rybrevant, Erleada, Darzalex |
| Daiichi Sankyo INC. | $1,202.15 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $1,157.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,045.37 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $943.43 | 2019-2025 | Jakafi, Monjuvi |
| Genzyme Corporation | $941.48 | 2019-2025 | |
| Amgen INC. | $886.29 | 2019-2025 | Lumakras, Evenity, Xgeva |
Show all 99 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $867.39 | 2019 | |
| Exelixis INC. | $854.90 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $841.13 | 2019-2025 | Tecentriq, Phesgo, Polivy |
| Celgene Corporation | $778.03 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Asd Specialty Healthcare, LLC | $762.61 | 2019-2025 | |
| Eisai INC. | $676.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $650.34 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Lilly USA, LLC | $550.67 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Abbvie INC. | $518.76 | 2019-2025 | |
| Seagen INC. | $477.70 | 2019-2023 | Tukysa, Adcetris, Padcev |
| Bayer Healthcare Pharmaceuticals INC. | $408.39 | 2019-2025 | |
| Sobi, INC | $392.35 | 2021-2025 | |
| Gilead Sciences, INC. | $376.94 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $368.70 | 2019-2025 | Gilotrif |
| Coherus Oncology, INC. | $346.31 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $300.75 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Alexion Pharmaceuticals, INC. | $296.65 | 2019-2025 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $290.61 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $288.70 | 2019-2025 | Nerlynx |
| Karyopharm Therapeutics INC. | $285.84 | 2020-2025 | Xpovio |
| Aveo Pharmaceuticals, INC. | $269.46 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $255.59 | 2021-2024 | Libtayo |
| Astellas Pharma US INC | $255.58 | 2019-2025 | Xtandi, Xospata, Padcev |
| Beigene USA, INC. | $237.53 | 2020-2024 | Brukinsa |
| Servier Pharmaceuticals LLC | $197.03 | 2021-2025 | |
| Emd Serono, INC. | $190.67 | 2019-2025 | |
| Spectrum Pharmaceuticals INC. | $183.55 | 2024-2025 | Rolvedon |
| Rigel Pharmaceuticals, INC. | $179.52 | 2019-2024 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $176.13 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Janssen Pharmaceuticals, INC | $161.65 | 2019-2024 | Xarelto, Rybrevant |
| Adaptive Biotechnologies Corporation | $158.22 | 2023-2025 | Clonoseq |
| Jazz Pharmaceuticals INC. | $153.32 | 2021-2025 | Zepzelca |
| Cumberland Pharmaceuticals, INC. | $152.41 | 2023-2025 | Sancuso |
| Kite Pharma, INC. | $145.49 | 2020-2025 | Yescarta |
| Taiho Oncology, INC. | $141.09 | 2019-2025 | |
| Pharmaessentia USA Corporation | $137.05 | 2022-2025 | Besremi |
| Secura Bio, INC. | $135.70 | 2019-2021 | |
| Clovis Oncology, INC. | $133.19 | 2019-2020 | |
| Genmab U.S., INC. | $121.97 | 2022-2025 | Tivdak, Epkinly |
| Deciphera Pharmaceuticals INC. | $107.52 | 2023-2025 | Qinlock, Romvimza |
| Dova Pharmaceuticals | $105.48 | 2019-2021 | |
| Novocure INC. | $101.94 | 2019-2024 | Optune, Optune Lua (Novottf-200t) |
| Organon LLC | $98.79 | 2021-2023 | Ontruzant |
| Adc Therapeutics America, INC. | $97.89 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $96.88 | 2019-2024 | Onivyde, Somatuline Depot |
| Alnylam Pharmaceuticals INC. | $89.80 | 2023-2025 | Givlaari |
| Azurity Pharmaceuticals, INC. | $89.23 | 2024-2025 | Vivimusta, Danziten |
| Fresenius Kabi USA, LLC | $88.50 | 2024-2025 | Stimufend |
| Cti Biopharma Corp. | $87.30 | 2022-2023 | Vonjo |
| Tersera Therapeutics LLC | $85.39 | 2020-2025 | Xermelo, Zoladex |
| Epizyme, INC. | $84.06 | 2020-2022 | |
| Acrotech Biopharma INC. | $83.98 | 2021-2025 | Beleodaq |
| Stemline Therapeutics INC. | $81.77 | 2023-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $72.00 | 2019-2022 | |
| Mylan Institutional INC. | $71.30 | 2019-2022 | |
| Partner Therapeutics, INC. | $67.53 | 2019-2020 | |
| Heron Therapeutics, INC. | $65.84 | 2019-2020 | |
| Cardinal Health 108 LLC | $62.59 | 2022 | |
| Celltrion USA INC. | $62.25 | 2023-2024 | Vegzelma |
| Beone Medicines USA, INC. | $60.14 | 2025 | Tevimbra, Brukinsa |
| Geron Corporation | $57.73 | 2025 | Rytelo |
| Myovant Sciences INC. | $57.27 | 2021-2022 | |
| Morphosys, US INC. | $54.64 | 2022-2023 | Monjuvi |
| Iovance Biotherapeutics, INC. | $54.51 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $51.84 | 2024-2025 | Orgovyx |
| Amag Pharmaceuticals, INC. | $51.29 | 2019 | |
| West Therapeutics Development, LLC | $49.44 | 2019-2020 | |
| Kyowa Kirin, INC. | $46.64 | 2019-2022 | |
| Tempus Ai, INC | $44.44 | 2025 | Xt Cdx |
| Horizon Therapeutics Plc | $42.26 | 2019-2021 | |
| Tg Therapeutics, INC. | $35.34 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $33.78 | 2023 | Sylvant |
| Immunogen, INC. | $31.98 | 2023-2024 | Elahere, Elahere |
| Verastem, INC. | $31.20 | 2019 | |
| Springworks Therapeutics, INC. | $31.18 | 2024-2025 | Ogsiveo |
| Blue Earth Diagnostics | $27.10 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $24.50 | 2023 | Avastin |
| Argenx US, INC. | $23.45 | 2022 | |
| Accord Healthcare, INC. | $23.37 | 2025 | |
| Hologic Sales and Service, LLC | $22.58 | 2024 | Trident Specimen Radiography System, Localizer |
| Fortovia Therapeutics, INC. | $20.78 | 2020 | |
| Legend Biotech USA INC. | $19.56 | 2024 | |
| Sirtex Medical INC | $18.20 | 2022 | |
| Syndax Pharmaceuticals, INC. | $18.10 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,386.05 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lerro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.